Free Trial

Relay Therapeutics (NASDAQ:RLAY) Stock Price Down 4.8% - Time to Sell?

Relay Therapeutics logo with Medical background

Relay Therapeutics, Inc. (NASDAQ:RLAY - Get Free Report)'s share price dropped 4.8% during mid-day trading on Tuesday . The stock traded as low as $4.53 and last traded at $4.55. Approximately 111,174 shares were traded during trading, a decline of 96% from the average daily volume of 2,951,053 shares. The stock had previously closed at $4.78.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on the stock. Leerink Partners reduced their price objective on shares of Relay Therapeutics from $19.00 to $18.00 and set an "outperform" rating on the stock in a research note on Wednesday, December 4th. HC Wainwright reissued a "buy" rating and issued a $16.00 price objective on shares of Relay Therapeutics in a research note on Tuesday. Finally, JMP Securities reiterated a "market outperform" rating and issued a $21.00 target price on shares of Relay Therapeutics in a report on Thursday, December 12th. One research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $20.50.

Check Out Our Latest Analysis on Relay Therapeutics

Relay Therapeutics Trading Up 13.0 %

The company's 50-day moving average is $4.71 and its two-hundred day moving average is $6.28. The firm has a market cap of $720.57 million, a P/E ratio of -1.65 and a beta of 1.60.

Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last announced its earnings results on Wednesday, November 6th. The company reported ($0.63) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.14. The firm's revenue was down 100.0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.54) EPS. Research analysts anticipate that Relay Therapeutics, Inc. will post -2.55 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CFO Thomas Catinazzo sold 6,802 shares of the firm's stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $6.06, for a total value of $41,220.12. Following the completion of the transaction, the chief financial officer now directly owns 306,391 shares in the company, valued at approximately $1,856,729.46. This trade represents a 2.17 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Peter Rahmer sold 32,156 shares of the business's stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $4.15, for a total transaction of $133,447.40. Following the transaction, the insider now directly owns 357,507 shares of the company's stock, valued at approximately $1,483,654.05. This represents a 8.25 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 162,319 shares of company stock worth $781,067 over the last quarter. 4.32% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. EverSource Wealth Advisors LLC bought a new position in shares of Relay Therapeutics in the second quarter worth approximately $37,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of Relay Therapeutics during the 3rd quarter worth $63,000. Portland Investment Counsel Inc. purchased a new position in Relay Therapeutics in the third quarter worth $71,000. Values First Advisors Inc. bought a new position in Relay Therapeutics in the third quarter valued at $75,000. Finally, Point72 DIFC Ltd purchased a new stake in Relay Therapeutics during the third quarter valued at about $134,000. 96.98% of the stock is owned by institutional investors.

Relay Therapeutics Company Profile

(Get Free Report)

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.

Featured Articles

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Relay Therapeutics Right Now?

Before you consider Relay Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.

While Relay Therapeutics currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Goldman Sachs’ 2025 Market Outlook: Top 3 Stock Picks
7 Stocks to Benefit From Trump’s Tariffs in 2025
Investing in Quantum Computing: Is Rigetti the Stock to Watch?

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines